Regenerative medicine crossing borders




Phase 1 of RegMed XB begins with three projects.

With partners from academia, industry, health foundations, and regional governments, RegMed XB has already funded three projects for five years. 

Taking steps towards a bioengineered joint. Taking steps towards a bioengineered joint. Knee osteoarthritis affects 250 million people worldwide. It involves the degeneration of knee joint cartilage and the underlying bone. Patients can experience severe pain accompanied by a decreased range of motion and reduced mobility. Osteoarthritis has no cure, so treatment involves reducing and managing pain, or surgical interventions such as a total joint replacement. Regenerative medicine can offer a new treatment, for example through a bioengineered joint replacement. The RegMed XB partners are coming together to take the first steps towards a bioengineered joint as a treatment and possible cure for osteoarthritis of the knee. 


A first subunit of a bioengineered kidney


A first subunit of a bioengineered kidney. There is a worldwide epidemic of end-stage kidney disease. At present, dialysis and transplantation are the only treatment options. In the Netherlands alone, 6,500 people currently depend on dialysis, approximately 1,300 of which will die this year. Regenerative medicine offers an alternative treatment in the form of a bioengineered kidney. In this first project, the RegMed XB partners will work towards creating a functioning subunit of a bioengineered kidney. This functional subunit is the nephron, of which there are approximately one million in the adult kidney.


A proof-of-concept therapy for type 1 diabetes


A proof-of-concept therapy for type 1 diabetes. Nearly 150,000 people in the Netherlands suffer from type 1 diabetes. In this disease, the insulin-producing β-cells in the islets of Langerhans of the pancreas are destroyed by an autoimmune reaction. Patients require lifelong insulin injections, often multiple times daily, and are at a high risk for secondary conditions, including blindness and kidney failure. Current treatments help manage the absence of islets, but there is no cure. The RegMed XB partners are working towards a proof-of-concept of a new therapy for type 1 diabetes.